Stryker Corporation (NYSE:SYK) – Northcoast Research increased their FY2017 earnings estimates for shares of Stryker in a report released on Friday. Northcoast Research analyst D. Keiser now expects that the medical technology company will post earnings of $6.49 per share for the year, up from their previous estimate of $6.48. Northcoast Research also issued estimates for Stryker’s Q4 2017 earnings at $1.96 EPS, Q2 2018 earnings at $1.66 EPS, Q3 2018 earnings at $1.70 EPS, Q4 2018 earnings at $2.13 EPS and FY2018 earnings at $7.09 EPS.

Other equities research analysts have also issued reports about the stock. Wells Fargo & Co upped their price objective on shares of Stryker from $160.00 to $166.00 in a research note on Friday, October 27th. Canaccord Genuity upped their price objective on shares of Stryker from $155.00 to $162.00 and gave the company a “buy” rating in a research note on Friday, October 27th. Stifel Nicolaus upped their price objective on shares of Stryker from $158.00 to $168.00 and gave the company a “buy” rating in a research note on Friday, October 27th. Cowen set a $160.00 price objective on shares of Stryker and gave the company a “buy” rating in a research note on Friday, October 6th. Finally, Royal Bank of Canada reissued a “buy” rating and set a $155.00 target price on shares of Stryker in a research note on Monday, October 2nd. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. Stryker has a consensus rating of “Hold” and a consensus target price of $156.60.

Shares of Stryker (NYSE:SYK) opened at $158.23 on Monday. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.37 and a quick ratio of 1.61. Stryker has a 12 month low of $119.17 and a 12 month high of $164.20. The company has a market cap of $59,215.68, a price-to-earnings ratio of 33.81, a PEG ratio of 2.26 and a beta of 0.78.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, beating the Zacks’ consensus estimate of $1.50 by $0.02. Stryker had a net margin of 14.67% and a return on equity of 24.11%. The company had revenue of $3.01 billion for the quarter, compared to analyst estimates of $2.97 billion. During the same period in the prior year, the firm posted $1.39 EPS. The company’s quarterly revenue was up 6.1% on a year-over-year basis.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 31st. Investors of record on Friday, December 29th will be paid a dividend of $0.47 per share. The ex-dividend date is Thursday, December 28th. This is a positive change from Stryker’s previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a yield of 1.19%. Stryker’s dividend payout ratio is currently 40.17%.

In other Stryker news, insider Lonny J. Carpenter sold 5,000 shares of the company’s stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $155.34, for a total transaction of $776,700.00. Following the transaction, the insider now owns 83,207 shares in the company, valued at $12,925,375.38. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 7.40% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SYK. Coldstream Capital Management Inc. raised its holdings in shares of Stryker by 3.7% in the second quarter. Coldstream Capital Management Inc. now owns 17,445 shares of the medical technology company’s stock valued at $2,421,000 after purchasing an additional 626 shares during the last quarter. Retirement Systems of Alabama raised its holdings in shares of Stryker by 2.5% in the third quarter. Retirement Systems of Alabama now owns 234,870 shares of the medical technology company’s stock valued at $33,356,000 after purchasing an additional 5,656 shares during the last quarter. Toronto Dominion Bank raised its holdings in shares of Stryker by 25.8% in the second quarter. Toronto Dominion Bank now owns 105,403 shares of the medical technology company’s stock valued at $14,625,000 after purchasing an additional 21,585 shares during the last quarter. Colonial Trust Advisors raised its holdings in shares of Stryker by 56.1% in the second quarter. Colonial Trust Advisors now owns 23,446 shares of the medical technology company’s stock valued at $3,254,000 after purchasing an additional 8,426 shares during the last quarter. Finally, Cornerstone Capital Management Holdings LLC. raised its holdings in shares of Stryker by 3.1% in the third quarter. Cornerstone Capital Management Holdings LLC. now owns 55,255 shares of the medical technology company’s stock valued at $7,847,000 after purchasing an additional 1,683 shares during the last quarter. Hedge funds and other institutional investors own 74.90% of the company’s stock.

WARNING: “FY2017 EPS Estimates for Stryker Corporation (SYK) Boosted by Analyst” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2018/01/15/fy2017-eps-estimates-for-stryker-corporation-syk-boosted-by-analyst.html.

About Stryker

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Earnings History and Estimates for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.